Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTx-265 (hCG + EPO) in Acute Ischemic Stroke
NCT00715364Phase 2Withdrawn
- Sponsor
- Stem Cell Therapeutics Corp.
- Start
- Aug 2009
- Primary completion
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of human chorionic gonadotropin, epoetin alfa in ischemic stroke, sponsored by Stem Cell Therapeutics Corp.. Planned start Aug 2009; status: withdrawn.
02
Drugs
human chorionic gonadotropinepoetin alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00715364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00715364.